IMPORTANT
SAFETY
INFORMATION FULL
PRESCRIBING
INFORMATION PATIENT
INFORMATION MEDICAL
INFORMATION PATIENT
SITE

INHIBIT DRY EYE

inflammation1

DON'T MAKE HER WAIT

CHOOSE XIIDRA

The ONLY nonsteroid anti-inflammatory Rx that can start to deliver dry eye symptom relief in just 2 WEEKS1*


SEE THE DATA HELP YOUR PATIENTS SAVE

*Xiidra significantly reduced symptoms of eye dryness at 2 weeks in 2 out of 4 clinical studies.1

Not an actual patient.

Xiidra Ken Jeong hero image

Not an actual patient.

INHIBIT DRY EYE

inflammation1

DON'T MAKE
HER WAIT

CHOOSE XIIDRA

The ONLY nonsteroid anti-inflammatory Rx that can start to deliver dry eye symptom relief in just 2 WEEKS1*

SEE THE DATA
HELP YOUR PATIENTS SAVE

*Xiidra significantly reduced symptoms of eye dryness at 2 weeks in 2 out of 4 clinical studies.1

FOOTNOTES

*Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in dry eye disease is not known.1,2,5

Your patient’s eyes deserve a change

Consider prescribing Xiidra, a first-in-class Rx therapy indicated for the treatment of the signs and symptoms of dry eye disease.1,2†

†Xiidra is an LFA-1 antagonist for the treatment of dry eye disease.1

Lasting symptom relief in 2 weeks icon

Potential Lasting symptom relief that can start in as early as 2 weeks‡

Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1

Check out the data
Address the signs of dry eye disease icon

Help Address the signs of dry eye disease

In 3 out of 4 studies, Xiidra showed notable improvements in signs (based on ICSS) of dry eye disease.1

Dive into the studies
Safety data in clinical trials icon

Safety data in clinical trials1

The adverse reactions of Xiidra were studied across 5 clinical trials.§

see the data
Access for your patients icon

Coverage matters

Xiidra has ~90% overall coverage for Medicare Part D and commercial patients nationwide.3||

Get more info

‡The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100). Effects on symptoms of dry eye disease: a larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease: at day 84, a larger reduction in ICSS favoring Xiidra was observed in 3 out of the 4 studies.1

§In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least 1 dose of lifitegrast (1287 of whom received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. One hundred-seventy patients were exposed to Xiidra for approximately 12 months. The most common adverse reactions (reported in 5-25% of patients) were instillation-site irritation, dysgeusia, and reduced visual acuity.1

||Based on data from October 2023. Up to 66% of Medicare Part D and 94% of commercial patients may be covered.3

 


Watch the Video

Xiidra is a unique Rx eye drop specifically designed to inhibit dry eye inflammation1


Watch the Video

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.